Pyxis Oncology is a clinical-stage biotechnology company developing next-generation immunotherapies that target the tumor microenvironment and modulate innate immune pathways. While primarily focused on oncology, the company's NLRP3 program has significant implications for neurodegenerative diseases, particularly Parkinson's disease.
| Attribute | Value |
|---|---|
| Founded | 2019 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Matthew Maurer |
| IPO | Nasdaq (NASDAQ: PYXS), 2023 |
| Focus | Immunotherapy, NLRP3 inhibitors |
| Stage | Phase 1/Preclinical |
Pyxis Oncology was founded based on research from the Dana-Farber Cancer Institute and Massachusetts General Hospital. The company's initial focus was on cancer immunotherapy, particularly antibodies targeting CD47 and related "don't eat me" signals.
In 2022, Pyxis expanded its pipeline to include NLRP3 inflammasome inhibitors, recognizing the role of neuroinflammation in both cancer metastasis to the brain and primary neurodegenerative diseases.
Pyxis's NLRP3 program is distinct from its oncology focus but leverages the same scientific expertise:
| Program | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| PYX-001 | Anti-CD47 antibody | Solid tumors | Phase 1 | Recruiting |
| PYX-002 | NLRP3 inhibitor | Parkinson's disease | Preclinical | Lead optimization |
| PYX-003 | SIRPα Fc fusion | Hematologic cancers | Phase 1 | Active |
| PYX-004 | NLRP3/TGF-β dual | Fibrosis | Discovery | Early stage |
PYX-002 is Pyxis's lead program for Parkinson's disease:
The company's oncology expertise informs its understanding of immune modulation in the brain tumor microenvironment, which shares features with neuroinflammation in PD.
Pyxis's technology platform includes:
PYX-001 (anti-CD47) is currently in Phase 1 clinical trials for solid tumors:
For PYX-002 (Parkinson's disease), Pyxis plans:
Pyxis has built a strong IP portfolio around its programs:
| Metric | Value |
|---|---|
| IPO date | October 2023 |
| IPO price | $16.00/share |
| Market cap (2024) | ~$150M |
| Cash runway | Through 2025 |
| Revenue | None (R&D stage) |
Pyxis occupies a unique position with both oncology and neurodegeneration programs:
| Company | Focus | Pyxis Differentiation |
|---|---|---|
| Olacteant | NLRP3 (Dapansutrile) | Clinical data, single target |
| NodThera | NLRP3 (NT-0796) | CNS focus, Phase 1 |
| Ventus | NLRP3 + Gasdermin | Dual mechanism |
| Pyxis | NLRP3 + CD47 | Platform approach |